Biomarin Pharmaceutical Stock Return On Asset
| BMRN Stock | USD 89.49 0.86 0.97% |
Biomarin Pharmaceutical fundamentals help investors to digest information that contributes to Biomarin Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Biomarin Stock. The fundamental analysis module provides a way to measure Biomarin Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biomarin Pharmaceutical stock.
As of the 23rd of April 2024, Return On Assets is likely to grow to 0.03. Biomarin | Return On Asset |
Biomarin Pharmaceutical Company Return On Asset Analysis
Biomarin Pharmaceutical's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Biomarin Pharmaceutical Return On Asset | 0.0163 |
Most of Biomarin Pharmaceutical's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biomarin Pharmaceutical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Biomarin Return On Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Biomarin Pharmaceutical is extremely important. It helps to project a fair market value of Biomarin Stock properly, considering its historical fundamentals such as Return On Asset. Since Biomarin Pharmaceutical's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Biomarin Pharmaceutical's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Biomarin Pharmaceutical's interrelated accounts and indicators.
Click cells to compare fundamentals
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Biomarin Total Assets
Total Assets |
|
Based on the latest financial disclosure, Biomarin Pharmaceutical has a Return On Asset of 0.0163. This is 100.19% lower than that of the Biotechnology sector and 100.07% lower than that of the Health Care industry. The return on asset for all United States stocks is 111.64% lower than that of the firm.
Biomarin Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biomarin Pharmaceutical's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Biomarin Pharmaceutical could also be used in its relative valuation, which is a method of valuing Biomarin Pharmaceutical by comparing valuation metrics of similar companies.Biomarin Pharmaceutical is currently under evaluation in return on asset category among related companies.
Biomarin Pharmaceutical ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Biomarin Pharmaceutical's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Biomarin Pharmaceutical's managers, analysts, and investors.Environment Score | Governance Score | Social Score |
Biomarin Fundamentals
| Return On Equity | 0.0351 | ||||
| Return On Asset | 0.0163 | ||||
| Profit Margin | 0.07 % | ||||
| Operating Margin | 0.04 % | ||||
| Current Valuation | 16.94 B | ||||
| Shares Outstanding | 189.78 M | ||||
| Shares Owned By Insiders | 0.84 % | ||||
| Shares Owned By Institutions | 99.16 % | ||||
| Number Of Shares Shorted | 3.06 M | ||||
| Price To Earning | 220.73 X | ||||
| Price To Book | 3.54 X | ||||
| Price To Sales | 7.23 X | ||||
| Revenue | 2.42 B | ||||
| Gross Profit | 1.61 B | ||||
| EBITDA | 261.98 M | ||||
| Net Income | 167.65 M | ||||
| Cash And Equivalents | 1.27 B | ||||
| Cash Per Share | 6.85 X | ||||
| Total Debt | 1.13 B | ||||
| Debt To Equity | 0.24 % | ||||
| Current Ratio | 5.15 X | ||||
| Book Value Per Share | 26.25 X | ||||
| Cash Flow From Operations | 159.26 M | ||||
| Short Ratio | 2.39 X | ||||
| Earnings Per Share | 0.87 X | ||||
| Price To Earnings To Growth | 0.76 X | ||||
| Target Price | 109.74 | ||||
| Number Of Employees | 3.4 K | ||||
| Beta | 0.32 | ||||
| Market Capitalization | 16.98 B | ||||
| Total Asset | 6.84 B | ||||
| Retained Earnings | (621.55 M) | ||||
| Working Capital | 1.78 B | ||||
| Current Asset | 1.09 B | ||||
| Current Liabilities | 445.46 M | ||||
| Net Asset | 6.84 B |
About Biomarin Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biomarin Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biomarin Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biomarin Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Biomarin Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biomarin Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biomarin Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Moving against Biomarin Stock
| 0.72 | PBH | Prestige Brand Holdings Financial Report 2nd of May 2024 | PairCorr |
| 0.62 | SUPN | Supernus Pharmaceuticals Financial Report 14th of May 2024 | PairCorr |
| 0.59 | RDY | Dr Reddys Laboratories Financial Report 8th of May 2024 | PairCorr |
| 0.59 | KROS | Keros TherapeuticsInc Financial Report 2nd of May 2024 | PairCorr |
| 0.58 | MRUS | Merus BV Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to Biomarin Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biomarin Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biomarin Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biomarin Pharmaceutical to buy it.
The correlation of Biomarin Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biomarin Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biomarin Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biomarin Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Biomarin Pharmaceutical Piotroski F Score and Biomarin Pharmaceutical Altman Z Score analysis. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Complementary Tools for Biomarin Stock analysis
When running Biomarin Pharmaceutical's price analysis, check to measure Biomarin Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomarin Pharmaceutical is operating at the current time. Most of Biomarin Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Biomarin Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomarin Pharmaceutical's price. Additionally, you may evaluate how the addition of Biomarin Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Stocks Directory Find actively traded stocks across global markets | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |
Is Biomarin Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.98 | Earnings Share 0.87 | Revenue Per Share 12.88 | Quarterly Revenue Growth 0.202 | Return On Assets 0.0163 |
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.